Form 8-K - Current report:
SEC Accession No. 0001140361-24-046728
Filing Date
2024-11-14
Accepted
2024-11-14 07:55:52
Documents
15
Period of Report
2024-11-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20038321_8k.htm   iXBRL 8-K 30487
2 EXHIBIT 99.1 ef20038321_ex99-1.htm EX-99.1 96224
6 image00001.jpg GRAPHIC 5266
  Complete submission text file 0001140361-24-046728.txt   282033

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA galt-20241114.xsd EX-101.SCH 4018
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE galt-20241114_lab.xml EX-101.LAB 21966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE galt-20241114_pre.xml EX-101.PRE 16068
17 EXTRACTED XBRL INSTANCE DOCUMENT ef20038321_8k_htm.xml XML 4243
Mailing Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071
Business Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071 678-620-3186
GALECTIN THERAPEUTICS INC (Filer) CIK: 0001133416 (see all company filings)

EIN.: 043562325 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-31791 | Film No.: 241457255
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)